Nucleic Acid Drug Delivery

"Nucleic Acid Drug Delivery: Triumphs and Challenges" explores the potential of RNA interference (RNAi) as a targeted cancer therapy, offering a more precise and effective alternative to conventional chemotherapy. The book discusses how RNAi, through small interfering RNA (siRNA) and microRNA (miRNA), can selectively silence oncogenes, thereby reducing the off-target effects and toxicity associated with traditional treatments. It also addresses the challenges of RNA delivery, focusing on advancements like lipid nanoparticles (LNPs) and other novel systems designed to enhance stability, bioavailability, and targeting efficiency. Additionally, the book highlights the clinical success of Patisiran, an FDA-approved RNAi-based drug, as a milestone in RNAi therapy, paving the way for broader applications in cancer treatment. With ongoing research and innovation, RNAi-based therapies offer a promising future in oncology, providing safer, more effective treatment options that could revolutionize cancer care. The book delves into these advancements while exploring the obstacles and the vast potential of nucleic acid-based drug delivery systems for improved therapeutic outcomes.